| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.7 | 3.0 |
| Gross profit | 0.4 | 0.2 |
| Profit before tax | 10.5 | -34.3 |
| Net income | 10.6 | -34.3 |
| EPS (diluted, $ a share) | $2.72 | $-23.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -11.4% |
|---|---|
| Gross margin | 16.2% |
| Operating margin | -126.4% |
10-Q filed with the SEC, NASDAQ: MEDS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
DataMeds AI, Inc.: key numbers
- Share price
- $0.6421Close, Nov 16
- Market cap
- $3.68M
- Shares outstanding
- 5.72MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from DataMeds AI, Inc.
All →DataMeds AI Capital Raise
DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.
- Counterparty
- Dawson James Securities, Inc.
DataMeds AI Financial Results
DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth driven by its Corexa Pharmacy drug dispensing business. The company achieved a net profit of $2.72 per share and regained full compliance with Nasdaq listing standards during the period. Key strategic developments included the launch of the Health Lives Here mobile app and the acquisition of the Helomics cancer diagnostics laboratory.
- Term
- Q3 2026
“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
DataMeds AI Deal Termination with EOS Technology Holdings, Inc.
DataMEDS AI, Inc. has terminated its Second Amended and Restated Letter of Intent (LOI) with multiple parties including EOS Technology Holdings, Scilex, and Datavault AI. The LOI contemplated the acquisition of intellectual property assets and a controlling interest in Tollo Health in exchange for common stock, but was cancelled due to market conditions. The company stated that no shares will be issued and no fees are owed as a result of the termination.
- Counterparty
- EOS Technology Holdings, Inc.
DataMeds AI M&A Deal with EOS Technology Holdings, Inc.
DataMEDS AI entered into a second amended and restated non-binding letter of intent to acquire intellectual property assets from EOS and Scilex Holding Company, and a controlling interest in Tollo Health (d/b/a Health Lives Here). The transaction involves an exchange of membership interests and the issuance of common stock that will result in the counterparties owning approximately 89.5% of the company's common stock on a fully diluted basis.
- Counterparty
- EOS Technology Holdings, Inc.
DataMeds AI Nasdaq/NYSE Compliance Notice
DataMeds AI, Inc. received formal notification from Nasdaq on October 19, 2026, confirming that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing. The company had previously been in deficiency since April 2026 and had also recently regained compliance with the minimum bid-price requirement in June 2026.
- Counterparty
- Nasdaq
DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M
DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.
- Value
- $2M
- Counterparty
- REBOOT Health AI, Inc.
- Term
- perpetuity